Previous 10 | Next 10 |
Exagen Inc. (NASDAQ: XGN) is one of today's top gainers. The company's shares have moved -3.21% on the day to $1.51. Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It...
2024-01-29 10:00:02 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-21 16:50:33 ET More on Pacific Biosciences of California, AVITA Medical, etc. AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now Reassessing Pacific Biosciences: Deep...
2024-01-08 01:28:08 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen For further details see: Exagen reaffirms FY23 revenue of at least $50M
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance. ...
2023-11-20 08:37:05 ET Exagen Inc. (XGN) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genu...
2023-11-17 16:21:55 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen For further details see: Exagen files for a $150M mixed shelf offering
2023-11-13 16:28:54 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen For further details see: Exagen GAAP EPS of -$0.31 beats by $0.15, revenue of $13.4M beats by $3.07M
SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. Recognized total revenue of $13.4 million for the third quarter of 2023. ...
News, Short Squeeze, Breakout and More Instantly...
Exagen Inc. Company Name:
XGN Stock Symbol:
NYSE Market:
CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announc...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial ...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...